Proteostasis and Diseases of the Motor Unit by Carlo Rinaldi et al.
fnmol-09-00164 December 26, 2016 Time: 10:42 # 1
PERSPECTIVE
published: 27 December 2016
doi: 10.3389/fnmol.2016.00164
Edited by:
Oliver Stork,
Otto von Guericke University
Magdeburg, Germany
Reviewed by:
Andrew P. Lieberman,
University of Michigan, USA
Maria Pennuto,
University of Trento, Italy
*Correspondence:
Carlo Rinaldi
carlo.rinaldi@dpag.ox.ac.uk
Received: 06 November 2016
Accepted: 19 December 2016
Published: 27 December 2016
Citation:
Rinaldi C, Mäger I and Wood MJ
(2016) Proteostasis and Diseases
of the Motor Unit.
Front. Mol. Neurosci. 9:164.
doi: 10.3389/fnmol.2016.00164
Proteostasis and Diseases of the
Motor Unit
Carlo Rinaldi*, Imre Mäger and Matthew J. Wood
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
The accumulation in neurons of aberrant protein species, the pathological hallmark
of many neurodegenerative diseases, results from a global impairment of key cellular
processes governing protein synthesis/degradation and repair mechanisms, also known
as the proteostasis network (PN). The growing number of connections between
dysfunction of this intricate network of pathways and diseases of the motor unit,
where both motor neurons and muscle are primarily affected, has provided momentum
to investigate the muscle- and motor neuron-specific response to physiological and
pathological stressors and to explore the therapeutic opportunities that manipulation of
this process may offer. Furthermore, these diseases offer an unparalleled opportunity
to deepen our understanding of the molecular mechanisms behind the intertissue
communication and transfer of signals of proteostasis. The most compelling aspect of
these investigations is their immediate potential for therapeutic impact: targeting muscle
to stem degeneration of the motor unit would represent a dramatic paradigm therapeutic
shift for treating these devastating diseases. Here we will review the current state of the
art of the research on the alterations of the PN in diseases of the motor unit and its
potential to result in effective treatments for these devastating neuromuscular disorders.
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THE PROTEOSTASIS NETWORK
The maintenance of proteome integrity is paramount for cellular and organismal health.
Mammalian cells typically express about 20,000 different proteins, which, as they are newly
synthesized, must adopt defined three-dimensional configurations to become functional (Balchin
et al., 2016). These folded structures are unstable, and proteins, particularly those partially or
entirely lacking ordered structure, can misfold under a number of stress conditions or unique
metabolic challenges, such as those occurring during cancer or aging, and accumulate in toxic
aggregates, the pathological hallmark of many human conditions, including Alzheimer’s and
Parkinson’s disease (Balchin et al., 2016). The state of proteome functional balance is commonly
referred as proteostasis and the cellular pathways involved in maintaining the integrity of
the proteome are collectively referred to as the proteostasis network (PN; Balch et al., 2008).
This network coordinates protein synthesis, folding, localization, and turnover and, given its
fundamental biological role, requires a tight control within individual cells, tissues, and organs.
The main players are chaperones and two proteolytic systems, the ubiquitin-proteasome and the
lysosome-autophagy systems, overall comprising almost 1400 components in mammalian cells,
which determine whether misfolded proteins will refold into their original stable conformation
or whether they will instead be eliminated (Powers et al., 2009) (Figure 1). Chaperones are
involved in all aspects of proteostasis: they promote the folding of newly synthesized proteins,
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FIGURE 1 | In eukaryotic cells, as nascent polypeptide chains emerge
from ribosomes, they are met by the chaperones and assisted in the
folding, which is necessary for a functional protein. Environmental
stress, aging, and mutations can tilt the balance toward formation of
misfolded proteins which tend to form toxic aggregates. These incorrectly
folded species are detected by a quality-control mechanism and targeted for
degradation by the cellular proteolytic systems or secreted via exosomes.
their translocation across membranes, and the refolding of
denatured substrates. Chaperones also prevent aggregation
of metastable proteins by targeting misfolded proteins for
degradation (Balchin et al., 2016) (Figure 1). In eukaryotic cells,
two distinct chaperone networks exist: the chaperones linked
to protein synthesis (CLIPS; Albanèse et al., 2010), which are
linked to the translation machinery and assist folding of newly
translated proteins, and the heat shock proteins (HSPs; Treweek
et al., 2015), which can be induced by the transcription factor heat
shock protein 1 (HSF1) and protect the proteome from stress.
Fatally misfolded proteins are polyubiquitinated by an enzymatic
E1/E2/E3 ubiquitination cascade and targeted for degradation
by the proteasome, the major eukaryotic proteolytic pathway
(Goldberg, 2003) (Figure 1). Misfolded proteins escaping
proteolysis by the ubiquitine-proteasome system (UPS) can reach
the lysosome through a membrane transporter in chaperone-
mediated autophagy (CMA; Cuervo et al., 2004) or organize
into oligomers and/or aggregates, which can be eliminated
also by lysosomes through macroautophagy (MA; Jackson and
Hewitt, 2016) (Figure 1). Numerous studies have highlighted
the importance of lysosomal degradation of misfolded proteins
in neurodegeneration: knock-down of autophagy genes, such as
Atg5 and Atg7, promotes toxicity in mouse models (Hung et al.,
2009; Pyo et al., 2013). Conversely, genetic or pharmacologic
activation of autophagy has a protective role in a number of
neurodegenerative diseases (Nah et al., 2015).
Another mechanism of clearance which is lately gaining
increasing interest connected with autophagy is via exosomes,
30–140 nm membrane-bound particles defined by their origin
from the endosomal pathway, which are emerging as pivotal
players in cellular signaling in both normal physiology and
disease states (Baixauli et al., 2014). Recent studies have shown
that they can transfer insoluble aggregates to neighboring cells,
resulting in a decreased toxic load on the proteome: whether
the spreading of protein aggregates via exosomes could provide
the molecular basis for the prion-like mechanism of disease
propagation in neurodegeneration is certainly very intriguing
(Yuyama et al., 2012; Schneider and Simons, 2013; Iguchi et al.,
2016) and has the potential to be exploited for therapeutic and
biomarker discovery (Boukouris and Mathivanan, 2015; Yuyama
et al., 2015).
The PN is highly redundant and all the components
are strongly interconnected: impairment of the UPS induces
compensatory autophagy, whereas knockdown of autophagy
components leads to the accumulation of proteasomal substrates
(Korolchuk et al., 2010; Park and Cuervo, 2013).
Additionally, both proteasomal and lysosomal clearance
pathways are tightly coupled to the chaperone systems via BAG-
domain proteins and specific ubiquitin ligases, such as the
cochaperone CHIP (Kabbage and Dickman, 2008). Interestingly,
as organisms age, quality control and the cellular response to
unfolded protein stress become compromised. Indeed, aging
is considered the principal risk factor for the onset of a
number of neurodegenerative disorders associated with aggregate
deposition (Balchin et al., 2016). Researchers are challenged to
develop an integrated view of the PN in health and disease in
order to further understand the basic mechanisms of cell function
and how loss of proteostasis leads to neurodegeneration.
PROTEOSTASIS AND DISEASES OF THE
MOTOR UNIT
A motor unit consists of one somatic efferent motor neuron
and all of the muscle fibers that it innervates, a concept
first introduced by Edward Liddell [1895–1981] and Charles
Sherrington [1857–1952] (Duchateau and Enoka, 2011). Because
an action potential generated by a motor neuron normally brings
to threshold all the muscle fibers it has contact with, a single
motor unit neuron constitutes the smallest power unit that can
be activated to generate movement.
Many diseases of the motor unit are caused by destabilizing
mutations that cause misfolding of the host protein, or alterations
in components of the protein homeostasis and quality control
machineries, overall suggesting a limited capacity to manage
proteome alterations (Table 1). Motor neurons are uniquely
sensitive to alterations in the PN due to their extreme polarization
and post-mitotic nature: they require tight temporal and spatial
regulation of protein translation and turnover and cannot rely
on the dilution of toxic waste occurring during cell division
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TABLE 1 | Diseases of the motor unit associated with mutations in components of the proteostasis network.
Proteostasis system Gene Disease Protein function Reference
Mutations causing protein misfolding AR SBMA Steroid-hormone activated transcription factor La Spada et al., 1991
SOD1 ALS Enzyme responsible for destroying free
superoxide radicals
Rosen et al., 1993
MYOT Myofibrillar
myopathy
Plays a significant role in the stability of thin
filaments during muscle contraction
Salmikangas et al., 1999
Chaperones DNAJB2 CMT2T,
DSMA5
Protein is implicated in protein folding and
protein complex dissociation
Blumen et al., 2012
HSPB8 CMT2L,
HMN2A
Small heat-shock protein implicated in
macroautophagy
Irobi et al., 2004
HSPB1 CMT2F, HMN Involved in stress resistance and actin
organization
Ackerley et al., 2006
DNAJB6 LGMD1D/LGMD1E Involved in protein folding and oligomeric
protein complex assembly
Speer et al., 1999
Ubiquitin-proteasome system UBQLN2 ALS Functionally links the ubiquitination machinery
to the proteasome
Deng et al., 2011
VCP IBMFTD/ALS Involved in 26S proteasome function, vesicle
transport and fusion, and assembly of
peroxisomes
Watts et al., 2004
Autophagy SQSTM1 ALS/FTD Multi-functional adapter protein that acts as a
critical regulator of degradation of ubiquitinated
proteins via the proteasome and autophagy
Fecto et al., 2011
OPTN ALS/FTD Can bind to the autophagy receptor SQSTM1
and regulate autophagy flux
Maruyama et al., 2010
ZFYVE26 SPG15 Involved in the formation and maturation of
autophagosomes
Hanein et al., 2008
Vesicle trafficking RAB7A CMT2B Regulates vesicle traffic in the late endosomes
and from late endosomes to lysosomes.
Verhoeven et al., 2003
SIMPLE CMT1C Integral membrane protein of lysosome/late
endosome
Street et al., 2003
CHMP2B ALS/FTD Component of the heteromeric ESCRT-III
complex that functions in the recycling or
degradation of cell surface receptors.
Skibinski et al., 2005
VAPB ALS/SMAFK Membrane protein involved in vesicle trafficking Nishimura et al., 2004
RNA processing HNRPA1/HNRPA2 IBMFTD/ALS RNA-binding protein that associates with
pre-mRNAs in the nucleus and influence
pre-mRNA processing, as well as other aspects
of mRNA metabolism and transport
Kim et al., 2013
TARDBP FTD/ALS DNA and RNA-binding protein, which regulates
transcription and splicing.
Sreedharan et al., 2008
FUS ALS Protein involved in pre-mRNA splicing and the
export of fully processed mRNA to the
cytoplasm.
Kwiatkowski et al., 2009
ATX2 ALS/SCA2 Potentially coordinates an active translation
complex
Pulst et al., 1996
SBMA, spinal and bulbar muscular atrophy; ALS, amyotrophic lateral sclerosis; CMT, Charcot-Marie-Tooth; DSMA, distal spinal and muscular atrophy; HMN, hereditary
motor neuropathy; LGMD, limb girdle muscular dystrophy; IBMFTD, inclusion body myositis, fronto-temporal dementia; SPG, spastic paraplegia; SCA, spino-cerebellar
ataxia; SMAFK, spinal muscular atrophy, Finkel type.
(Tanaka and Matsuda, 2014). On the other side, systems of
protein quality control and in particular fine-tuning the balance
between protein synthesis and protein degradation are crucial
for the maintenance of muscle mass. Excessive or defective
activity of the autophagy-lysosome or ubiquitin-proteasome in
acquired or inherited muscle disorders lead to detrimental effects
on muscle homeostasis and function (Sandri, 2013). Like in
other neurodegenerative diseases, the pathological hallmark of
many diseases of the motor unit is the presence of ubiquitin-
positive inclusions consisting of misfolded protein aggregates
in the affected cells (Hasegawa and Arai, 2007). Several studies
have shown that these aggregated structures or, more likely,
their oligomeric precursors, directly exert neurotoxic effects
by inducing proteotoxic stress and disturbing homeostasis
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(Ross and Poirier, 2005). Also large aggregates are believed to
contribute to the toxicity by sequestering functional proteins and
interfering with the UPS and the autophagic degradative pathway
(Olzscha et al., 2011). Similarly to alterations in proteostasis
in motor neurons, in sporadic and familial inclusion-body
myositis (s-IBM), a highly prevalent adult-onset degenerative
muscle disease, several proteins, including amyloid-β42 and its
oligomers, and phosphorylated tau abnormally accumulate in
aggregates, suggesting the presence of similar responses across
tissues to proteotoxic insults (Mastaglia and Needham, 2015).
Over the past decade, several observations in a group of
neurodegenerative diseases have also highlighted important links
between protein aggregation and RNA biology (Belzil et al.,
2013). A conspicuous number of RNA binding proteins (RBPs)
have been shown to be associated with amyotrophic lateral
sclerosis (ALS) or other neuromuscular diseases: for example,
mutations in RBPs such as hnRNPA1 and A2B1, TDP-43, and
FUS are associated with ALS (Table 1) (Kabashi et al., 2008; Kim
et al., 2013; Qiu et al., 2014). The current prevalent working
model suggests that mutations in RBPs enhance dramatically
their intrinsic tendency to form stable amyloid structures (Kim
et al., 2013), which results in accumulation of ribonucleoproten
(RNP) aggregates, disruption of RNA homeostasis or ‘ribostasis,’
and eventually cell death (Ramaswami et al., 2013). Because
amyloid initiation is a stochastic event dependent on protein
levels, any alteration that increases the local concentration of
RBPs in stress granules, such as defects in clearance mechanisms
due to VCP mutations, increases its frequency. This may explains
why redistribution of the RBP TDP-43 from the nucleus to
cytoplasmic inclusions is a hallmark pathological feature of most
sporadic and familial forms of ALS and frontotemporal lobar
degeneration (FTLD) (Winton et al., 2008). Recent evidence have
also highlighted that components of the protein quality control
system, such as Hsp70 proteins, survey RNP compositions by
influencing mRNA biology (Gilks et al., 2004), suggesting that
ribostasis is strongly coupled to the proteostatic state of the cell
(Walters and Parker, 2015).
THE PROTEOSTASIS NETWORK AS
TARGET FOR THERAPY FOR DISEASES
OF THE MOTOR UNIT
The lack of available treatments in the clinic combined with
the increasing burden of neurodegenerative disorders in the
aging population urgently require the development of effective
therapeutic approaches to arrest, stabilize, or reverse the
progression of these diseases. As a result of the intrinsic
property of the PN to achieve and maintain proteome balance,
a single PN modulator has the potential to restore proteostasis
in multiple diseases of protein conformations, while both
decreasing the levels of the toxic protein and alleviating its
pathogenic effects (Balchin et al., 2016). This approach, alone or
in synergistic combination with standard single-target therapies
(i.e., antisense oligonucleotides), may be more suitable for
the complex mechanisms of disease pathogenesis, therefore
increasing the chances of success in clinical trials. The use
of high throughput screening method to discover molecules
able to restore the proteostatic imbalance is rapidly gaining
momentum; therapeutic strategies that target the PN are now
emerging as promising avenues for the treatment of diseases
of protein conformation, based on recent evidence showing
that manipulation of the PN in in vitro and in vivo models
are able to suppress the toxicity associated with accumulation
of misfolded proteins (Rivas et al., 2015). The ubiquitin
proteasome system (UPS) and autophagy have a key role in
proteostasis by clearance of proteins and removal of damaged
and dysfunctional cellular components. These pathways are
essential for normal physiology and development, and are
also involved in numerous diseases including cancer and
neurodegeneration. Not unexpectedly, these two proteostatic
machineries are highly desirable therapeutic targets to improve
diseases caused by a mechanism of proteotoxicity (Vidal René
et al., 2014; Chondrogianni et al., 2015). Recently, a small-
molecule inhibitor of USP14, a deubiquitinating enzyme that
inhibits proteasomal degradation by removing the polyubiquitin
chain from the client proteins, was shown to enhance degradation
of aggregation-prone proteins, suggesting that manipulation of
the ubiquitin-proteasome system could be an attractive target to
promote the clearance of toxic protein (Lee et al., 2010). The
curcumin analog ASC-JM17 ameliorates the disease phenotype in
animal models of spinal and bulbar muscular atrophy (SBMA) by
targeting the mutant protein, androgen receptor, for degradation
via the UPS and simultaneously increasing oxidative stress
resistance via activation of the Nrf1 and Nrf2 pathway (Bott et al.,
2016). Targeting autophagy may also have therapeutic benefits,
as compounds that increase protein turnover by induction of
the autophagic activity mitigate neurodegeneration and enhance
protein clearance in neuronal models of TDP-43 aggregation
(Wang et al., 2012).
Another approach is represented by small molecules that
modulate the activity of chaperone proteins, such as Hsp90 and
Hsp70, which have essential roles in preventing aberrant protein–
protein interactions and promoting correct protein folding (West
et al., 2012). The appearance of aggregated proteins, as occurs in
diseases of misfolded protein, indicates that the quality control
pathways of the PN become compromised, leading to cellular
dysfunction and death. Pharmacological agents that increase HSP
levels by inducing the heat shock response, such as 17-AAG or
arimoclomol have been shown to counteract the toxicity caused
by accumulation of toxic proteins in models of SBMA, ALS,
and IBM (Kieran et al., 2004; Waza et al., 2005; Ahmed et al.,
2016). Interestingly, arimoclomol does not induce the heat shock
response in unstressed cells, thereby avoiding the potential side
effects associated with widespread heat shock response activation
(Kieran et al., 2004; Ahmed et al., 2016). Despite the beneficial
effects in preclinical models, several factors need to be considered
in order to translate this approach into valuable therapeutic
options: the high degree of integration makes manipulation of
the PN a challenging task, where the risk of compromising the
stability of other proteins will need to be addressed (Balch et al.,
2008; Balchin et al., 2016). Also, for conformational diseases
involving the motor unit, the proteostasis modulators will need
to achieve targeted drug delivery in motor neurons and muscle.
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Researchers are challenged to develop a better understanding
of the complex interplay between molecules, cells, and tissues
in order to answer these questions and before moving these
strategies into the clinic.
INTERCELLULAR PROTEOSTASIS: A
COORDINATED RESPONSE OF TISSUES
AND ORGANS TO PROTEOTOXIC
INSULTS
While the central components of protein quality control function
autonomously within each cell, it has been recently demonstrated
that the PN is also regulated by cell-non-autonomous signaling
through communication between subcellular compartments and
across different cells and tissues (van Oosten-Hawle et al., 2013).
In the evolution from unicellularity to multicellularity, organisms
have developed mechanisms of intercellular cooperation in
order to protect tissues with intrinsic reduced buffering
capacity, such as neurons, and promote a rapid, predictive, and
adaptive response to proteotoxic insults (van Oosten-Hawle and
Morimoto, 2014).
Most of the discoveries in non-cell-autonomous proteostasis
have been made in invertebrates, although evidence of a similar
process is starting to emerge also in mammals (Zeineddine
and Yerbury, 2015). In Caenorhabditis elegans, it has been
shown that the heat shock response of somatic cells is regulated
by thermosensory neurons that detect temperature changes to
control HSF-1 activity throughout the organism (Prahlad et al.,
2008). These signaling responses are bidirectional and non-
neuronal tissues such as gonad, intestine, or muscle tissue
communicate conditions of altered proteostasis with each other
and back to the nervous system independently of neural control
via autocrine/paracrine and endocrine mechanisms. For example,
expression of metastable myosin restricted to muscle cells of
Caenorhabditis elegans induces a compensatory stress response
not only in muscle but also in neuronal and intestinal cells,
which relies upon transcriptional feedback regulated by the
FoxA transcription factor PHA-4 (van Oosten-Hawle et al.,
2013). The motor unit functionally largely relies on anterograde
and retrograde signaling at the neuromuscular junction (NMJ):
the nature of these signals, particularly from muscle to motor
neurons, and the specific molecular mechanisms regulating
NMJ structure, function and maintenance are only beginning
to be elucidated (Yumoto et al., 2012), mainly due to the
technical challenges of studying this complex interaction at the
subcellular level. Diseases of the motor unit, such as SBMA
and spinal muscular atrophy (SMA), where a mechanism of
selective neuronal vulnerability has been challenged by recent
evidence showing that therapies exclusively targeting muscle
ameliorate the motor neuron pathology and rescue the disease
phenotype in animal models (Boyer et al., 2013), represent
an ideal working model to unravel the mechanisms of such
interaction. Furthermore, the most compelling aspect of these
findings is their potential for therapeutic impact: the possibility of
manipulating proteostasis in muscle for stemming degeneration
of motor neurons, which are less accessible for therapeutic
intervention, would represent a dramatic paradigm shift for the
treatment of these yet incurable devastating diseases.
Understanding how the signals of proteostasis are transmitted
from one cell to another, how they are integrated in a network
and which are the functional implications of such intercellular
and intertissue communication in aging and diseases is crucial.
In order to boost the organismal proteostasis capacity, it has
been recently shown that under conditions of stress, cells can
transfer cellular material ranging from stress signals to whole
organelles, such as lysosomes, mitochondria, endosomes and
lipid droplets through tunneling nanotubes, thin membranous,
freely hovering channels with a diameter of 50–200 nm
(Astanina et al., 2015; Burtey et al., 2015; Wang et al., 2016).
Another mechanism of distant intercellular communication that
is currently gaining considerable interest is via extracellular
vesicles (Tkach and Théry, 2016). Recent studies suggest that
exosomes mediate the non-cell-autonomous control of a number
of physiological responses, including organismal proteostasis,
by releasing their cargo (RNAs and proteins) to recipient
cells and regulating the expression of target genes (Lee et al.,
2012). In addition, (i) proteotoxic insults induce the exosome-
mediated secretion of HSPs (Takeuchi et al., 2015; Kowal et al.,
2016); (ii) adding chaperone-containing exosomes to cultured
cells expressing aggregation-prone proteins restores the protein-
folding environment in recipient cells (Takeuchi et al., 2015); and
(iii) suppression of polyglutamine-mediated neurodegeneration
by remote tissue-specific expression of Hsp40 in Drosophila
depends on Ykt6, an R-SNARE protein necessary for exosome
FIGURE 2 | Protein annotations of specific Gene Ontology (GO) terms
were downloaded from the QuickGO database (http://www.ebi.ac.uk
/QuickGO/) and cross-referenced with selected EV proteomes from
the Vesiclepedia database (http://microvesicles.org, PMID: 23271954).
Only those experiments from Vesiclepedia that described exosome or
microvesicle proteomes with >500 detected proteins from Homo sapiens or
Mus musculus samples were included in the analysis. These selection criteria
were matched by 53 studies in the Vesiclepedia database where EVs were
derived from various cell types (e.g., cell lines, biofluids, primary tumor cells,
lymphocytes, myoblasts, platelets, endothelial cells and mesenchymal stem
cells). According to the Vesiclepedia database, on average 5.2% of EV
proteins are related to protein folding (GO:0006457), 4.1% are related to
autophagy (GO:0006914), and 3.4% are related to ubiquitin-dependent
proteasomes (GO:0043161). Furthermore, on average 11.5% of EV proteins
are related to proteins to any of those processes. Error bars represent
standard deviation.
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secretion (Takeuchi et al., 2015). Here we show that exosome or
microvesicle proteomes derived from various cell types including
myoblasts, platelets, endothelial cells and mesenchymal stem cells
contain on average of 11.5% proteins related to protein folding,
the ubiquitin proteasome, or autophagy (Figure 2), suggesting
possible PN-related functions of extracellular vesicles as a whole
or in their certain subtype. Upon understanding of their biology,
it may be possible to use exosomes as vehicle for delivery of
therapeutic factors to target tissues (El Andaloussi et al., 2013).
CONCLUDING REMARKS
Given the close ties with proteostasis and diseases of the motor
unit, insights into the mechanisms of protein quality control will
ultimately impact research striving to decode the pathogenesis
of these diseases. In recent years a better understanding of
the intracellular systems that govern proteostasis has formed
the rationale for numerous successful attempts to target
cellular proteostasis to counteract the toxicity related to several
neurodegenerative conditions in experimental models. Possible
therapeutic approaches include drugs that inhibit toxic aggregate
formation, activate protective mechanisms, or promote clearance
of toxic aggregates, which might have both prophylactic
and therapeutic benefits. Many unresolved issues still remain:
understanding why cells occasionally fail to compartmentalize
misfolded toxic species, allowing them to interfere with normal
protein homeostasis, and how the information of the status
of proteostasis is communicated between tissues will be
instrumental in elucidating the etiology of these diseases. The
possibility that exosomes may function in close relation with
autophagy pathway to preserve protein and RNA homeostasis
and to mediate the spreading of signals to surrounding cells in
order to coordinate organismal systemic responses is intriguing
and is a new exciting subject of investigation. Dissecting the
complex interplay of proteostasis between different tissues using
the motor unit as a working model offers the unparalleled
opportunity to gain insight into the general mechanisms of
protein quality control and has the potential to provide targets
for treatment for these yet incurable conditions.
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